- Home
- SVII vs INBX Comparison
SVII vs INBX Comparison
Compare SVII & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- INBX
- Stock Information
- Founded
- SVII 2021
- INBX 2010
- Country
- SVII United States
- INBX United States
- Employees
- SVII N/A
- INBX N/A
- Industry
- SVII Blank Checks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- INBX Health Care
- Exchange
- SVII Nasdaq
- INBX Nasdaq
- Market Cap
- SVII 248.9M
- INBX 237.5M
- IPO Year
- SVII 2022
- INBX 2020
- Fundamental
- Price
- SVII $11.30
- INBX $15.60
- Analyst Decision
- SVII
- INBX Hold
- Analyst Count
- SVII 0
- INBX 1
- Target Price
- SVII N/A
- INBX N/A
- AVG Volume (30 Days)
- SVII 9.2K
- INBX 120.3K
- Earning Date
- SVII 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- SVII N/A
- INBX N/A
- EPS Growth
- SVII 36.87
- INBX N/A
- EPS
- SVII 0.37
- INBX 118.83
- Revenue
- SVII N/A
- INBX $1,687,000.00
- Revenue This Year
- SVII N/A
- INBX N/A
- Revenue Next Year
- SVII N/A
- INBX N/A
- P/E Ratio
- SVII $30.53
- INBX $0.13
- Revenue Growth
- SVII N/A
- INBX 24.26
- 52 Week Low
- SVII $10.72
- INBX $10.80
- 52 Week High
- SVII $11.32
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- SVII 71.27
- INBX 53.53
- Support Level
- SVII $11.20
- INBX $14.67
- Resistance Level
- SVII $11.23
- INBX $16.35
- Average True Range (ATR)
- SVII 0.01
- INBX 0.61
- MACD
- SVII 0.01
- INBX -0.09
- Stochastic Oscillator
- SVII 80.00
- INBX 55.74
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.